pharmanewsdaily
1509 posts
Curi Bio acquires Dana Solutions to boost drug discovery platforms
Curi Bio, a developer of human iPSC-based platforms for drug discovery, has acquired Dana Solutions, a provider of…
July 25, 2020
Novavax NVX-CoV2373 COVID-19 vaccine candidate to be manufactured by FDB
Novavax has signed an agreement with FUJIFILM Diosynth Biotechnologies (FDB), a US-based contract development and manufacturing organization (CDMO),…
July 24, 2020
Olema Oncology raises $54m for breast cancer drug candidate OP-1250
Olema Oncology, a California-based biopharma company focused on developing targeted therapies for women’s cancers, has raised $54 million…
July 23, 2020
Ampio Pharmaceuticals begins phase 1 trial of Ampion for COVID-19 treatment
Ampio Pharmaceuticals has started a phase 1 clinical trial in the US for assessing its immunomodulatory anti-inflammatory agent…
July 23, 2020
BNT162 COVID-19 vaccine candidate : US govt signs $2bn supply deal with Pfizer and BioNTech
Pfizer and BioNTech have bagged a $1.95 billion deal with the US government for supplying 100 million doses…
July 22, 2020
Tenzing to acquire clinical-stage pharma company Reviva Pharmaceuticals
Tenzing Acquisition has agreed to acquire Reviva Pharmaceuticals, a California-based clinical-stage pharma company, focused on developing therapies for…
July 21, 2020
COV001 clinical trial results : Oxford vaccine ChAdOx1 nCoV-19 triggers strong immune response
COV001 clinical trial results : AstraZeneca and Oxford University said that interim results from the phase 1/2 COV001…
July 20, 2020
G42 Healthcare begins late-stage trial for Sinopharm COVID-19 vaccine
Find out how Sinopharm and G42 Healthcare are advancing the world’s first phase 3 COVID-19 vaccine trial in the UAE.
July 20, 2020
Farxiga : AstraZeneca gets FDA fast track status for heart failure after MI
AstraZeneca has secured fast track designation for Farxiga (dapagliflozin) in the US for its use in reducing the…
July 20, 2020
Celltrion begins phase 1 human trial of COVID-19 antiviral antibody candidate
Celltrion Group, a South Korean pharma company, has launched a phase 1 human clinical trial of a potential…
July 19, 2020